論文一覧

  1. Histological and biochemical evaluation of transforming growth factor-β activation and its clinical significance in patients with chronic liver disease.
    https://www.ncbi.nlm.nih.gov/pubmed/30815603
    Yokoyama H, Masaki T, Inoue I, Nakamura M, Mezaki Y, Saeki C, Oikawa T, Saruta M, Takahashi H, Ikegami M, Hano H, Ikejima K, Kojima S, Matsuura T.
    Heliyon. 2019 Feb 16;5(2):e01231. doi: 10.1016/j.heliyon.2019.e01231. eCollection 2019 Feb.

  2. Pancreatic cancer screening in patients with presumed branch-duct intraductal papillary mucinous neoplasms.
    https://www.ncbi.nlm.nih.gov/pubmed/30815373
    Torisu Y, Takakura K, Kinoshita Y, Tomita Y, Nakano M, Saruta M.
    World J Clin Oncol. 2019 Feb 24;10(2):67-74. doi: 10.5306/wjco.v10.i2.67. Review.

  3. Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
    https://www.ncbi.nlm.nih.gov/pubmed/30851422
    Yokoyama-Mashima S, Yogosawa S, Kanegae Y, Hirooka S, Yoshida S, Horiuchi T, Ohashi T, Yanaga K, Saruta M, Oikawa T, Yoshida K.
    Cancer Lett. 2019 Jun 1;451:100-109. doi: 10.1016/j.canlet.2019.02.046. Epub 2019 Mar 6.

  4. Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT.
    https://www.ncbi.nlm.nih.gov/pubmed/31302791
    Nishimura T, Mitsunaga M, Ito K, Kobayashi H, Saruta M.
    Gastric Cancer. 2020 Jan;23(1):82-94. doi: 10.1007/s10120-019-00988-y. Epub 2019 Jul 13.

  5. The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer.
    https://www.ncbi.nlm.nih.gov/pubmed/31284594
    Takakura K, Kawamura A, Torisu Y, Koido S, Yahagi N, Saruta M.
    Int J Mol Sci. 2019 Jul 6;20(13). pii: E3331. doi: 10.3390/ijms20133331. Review.

  6. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.
    https://www.ncbi.nlm.nih.gov/pubmed/31456946
    Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, Kajihara M, Saruta M.
    Front Oncol. 2019 Aug 13;9:762. doi: 10.3389/fonc.2019.00762. eCollection 2019. Review.

  7. High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer.
    https://www.ncbi.nlm.nih.gov/pubmed/31545443
    Sawada R, Arai Y, Sagawa Y, Nagata Y, Nishimura T, Noguchi M, Amano K, Arihiro S, Saruta M, Homma S.
    Oncol Rep. 2019 Nov;42(5):2057-2064. doi: 10.3892/or.2019.7304. Epub 2019 Sep 6.

  8. IgM response is a prognostic biomarker of primary billiary cholangitis treated with ursodeoxycholic acid and bezafibrate
    Takano K, Saeki C, Oikawa T, Hidaka A, Mizuno Y, Ishida J, Takakura K, Nakano M, Torisu Y, Amano K, Ishikawa T, Zeniya M, Tsubota A, Saruta M.
    Journal of Gastroenterology and Hepatology. 2019 Nov 1.doi:1.1111/jgh.14900

  9. Comparative assessment of sarcopenia using the JSH, AWGS, and EWGSOP2 criteria and the relationship between sarcopenia, osteoporosis, and osteosarcopenia in patients with liver cirrhosis.
    Saeki C, Oikawa T, Kanai Tomoya, Nakano M, Torisu Y, Sasaki N, Abo M, Matsuura T, Tsubota A, Saruta M.
    BMC Musculoskelet Disord. 2019 Dec 26;20(1):615.doi:10.1186/s12891-019-2983-4.

  10. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
    https://www.ncbi.nlm.nih.gov/pubmed/31287877
    Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, Amano K, Kato K, Hamaguchi T, Shimada Y, Saruta M, Boku N.
    Jpn J Clin Oncol. 2019 Dec 18;49(11):1004-1008. doi: 10.1093/jjco/hyz104.